• Spruce Biosciences (SPRB) is a high-risk, milestone-driven opportunity: track the expected BLA submission and FDA review, while recognizing that approval and commercial success in a very small patient population are uncertain.
• The apparent Liquidia (LQDA) thesis is conditional on a favorable patent appeal and continued access to its ILD indication; the cited $50+ scenario is speculative, so verify the company and current legal status before considering a trade.
• Nautilus Biotechnology (NAUT) drew a bearish short opinion, but the discussion provides too little evidence for a short thesis; investigate its revenue trajectory and product progress before acting.

Nautilus Biotechnology (NAUT)

• Shkreli was strongly skeptical of NAUT, describing it as a roughly $2 stock and questioning whether its business prospects justified investor interest.
• The discussion cites only $190,000 in revenue for the prior quarter and questions whether the next quarter would be substantially better. The speakers disagreed about whether Nautilus should be considered a drug company; no concrete near-term product or revenue catalyst was identified.
• Shkreli said he wanted to short the stock after hearing the caller’s case. That was his stated view, not evidence that the stock will decline.

Takeaways

• The discussion raises a basic diligence question: can Nautilus turn its technology into meaningful, growing revenue? Review its filings and product updates rather than relying on social-media promotion.
• The transcript offers a bearish opinion but little detail about the company’s technology, finances, or valuation, so it is not enough on its own to establish a short thesis.

Spruce Biosciences (SPRB)

• Spruce is developing an enzyme replacement therapy for Sanfilippo syndrome, a rare and serious disease. Shkreli said he believes the drug works and expects the company to pursue approval.
• He said Spruce planned to submit a BLA (Biologics License Application) that quarter. He suggested FDA approval could follow in roughly five to six months after submission, though that timing is not guaranteed.
• Shkreli said the stock could double or triple after the regulatory milestone. He also cautioned that approval would not settle the investment case: investors would still need to assess the commercial launch and sales.
• The treatment is aimed at a very small patient population. Shkreli said there may be only 500 to 1,000 patients worldwide and described the potential treatment cost as $500,000 to $1 million per patient per year, with payment potentially covered by insurers or governments.

Takeaways

• The thesis depends on regulatory progress and, ultimately, a successful launch in a very small market. Track the BLA submission, FDA review, and evidence of patient access and sales.
• The potential price appreciation cited is Shkreli’s speculative view, not a stated certainty. A delayed review or weaker-than-expected launch could undermine the thesis.

Abivax (ABVX)

• Shkreli described Abivax as a biotech whose stock had fallen while some other biotech shares were rising. He said stock movements can be driven by sector sentiment, investors’ competing opportunities, and portfolio flows—not just company-specific developments.
• He referred to Abivax’s work related to Crohn’s disease and ulcerative colitis, but offered no new clinical or regulatory update in this discussion.
• He used Abivax as an example of how a company can struggle to attract capital when investors prefer other areas, such as semiconductors and AI.

Takeaways

• The discussion presents Abivax as a high-risk biotech investment affected by both company prospects and broader market sentiment.
• The transcript provides no specific catalyst, valuation, or price target. Investors would need to review the company’s clinical data and upcoming milestones independently.

Praxis Precision Medicines (PRAX)

• Shkreli said he likes Praxis and noted that it is held by investors he characterized as especially knowledgeable.
• He did not explain the investment thesis or discuss a specific catalyst, valuation, or price target.

Takeaways

• The favorable mention is a starting point for research, not a complete investment case. The transcript does not provide enough detail to assess Praxis’s prospects.

Revolution Medicines (RVMD)

• Shkreli cited Revolution Medicines as one of the biotech stocks that had experienced a strong run, contrasting it with the weakness in Abivax and Spruce.
• He did not discuss Revolution’s business outlook, valuation, or a specific recommendation.

Takeaways

• The mention is primarily about relative performance and sector sentiment. It does not establish a view on whether the stock is attractive at its current price.

Moderna (MRNA)

• Moderna was also cited as a biotech stock that had risen while some other biotech shares, including Abivax and Spruce, had fallen.
• No company-specific outlook or investment recommendation was given.

Takeaways

• The transcript illustrates that biotech stocks can diverge sharply even within the same sector. It provides no basis for a standalone conclusion about Moderna’s value or prospects.

SanDisk (SNDK)

• Shkreli used SanDisk as an example of an investment that might attract capital away from biotech. In his hypothetical, a portfolio manager favored buying SanDisk over Abivax because of interest in AI-related stocks.
• This was an illustration of competition for investor capital, not a direct recommendation to buy SanDisk.

Takeaways

• The discussion suggests AI-related opportunities may draw attention and money away from biotech, potentially affecting biotech share prices regardless of company news.
• No SanDisk-specific valuation analysis or price target was provided.

Intel (INTC)

• Intel was briefly mentioned in a fragment—“looking like a hundred”—but the meaning was unclear. The transcript does not establish whether this referred to a share-price target or something else.
• No clear investment view or supporting analysis was provided.

Takeaways

• There is not enough context in the transcript to draw an actionable conclusion about Intel.

Biohaven (BHVN)

• Shkreli said Biohaven would be “a good one to look at,” without explaining why or specifying whether he was bullish or bearish.
• No catalyst, price target, or company-specific analysis was provided.

Takeaways

• Treat this as a prompt for further research only; the transcript does not supply an investment thesis.

Liquidia (likely LQDA; company not named in the excerpt)

• The closing discussion appears to concern a biotech company in a patent dispute with United Therapeutics, involving an interstitial lung disease (ILD) indication. The references are consistent with Liquidia, but the company is not named in the excerpt.
• Shkreli said the outcome could depend on the status of a patent appeal and whether the ILD indication remains available. He argued that removing the treatment from use could disrupt patients’ care, and compared the situation with a court decision involving contact lenses.
• He said that if the ILD issue were resolved favorably, he could see the stock reaching $50 or more. This was a conditional opinion, not a guaranteed outcome. He also acknowledged that the legal interpretation and outcome were uncertain.

Takeaways

• If this identification is correct, the investment case discussed is heavily dependent on patent litigation, the appeal, and the treatment’s label or market access.
• The stated $50-or-more scenario is speculative and contingent on a favorable outcome. Verify the company and current legal status before relying on this discussion.

Biotechnology and rare-disease treatments

• Shkreli described biotech as a high-risk, high-reward sector where share prices can move because of broader market conditions and investors’ alternative opportunities, even when there is no major company-specific news.
• He discussed enzyme replacement therapy for rare diseases, noting that treatments can improve patients’ lives but are not necessarily cures. He referenced Genzyme, Sanofi, and Takeda as companies associated with existing enzyme replacement therapies.
• He also emphasized that rare-disease businesses may serve very small patient populations, while potentially charging high annual treatment prices. Those economics do not by themselves guarantee approval, reimbursement, or commercial success.

Takeaways

• For biotech investments, distinguish between clinical or regulatory progress and the separate question of whether a treatment can be launched and sold successfully.
• Consider both company-specific milestones and sector-wide investor sentiment. The transcript’s examples show that biotech shares can be volatile and may require a long investment horizon.

AI, semiconductors, and technology spending

• Shkreli questioned whether new AI models would be bullish or bearish for semiconductors. He suggested that stronger AI offerings could support demand for computing equipment, but could also hurt some companies’ revenues and affect their spending on machines.
• AI and semiconductor stocks were presented as competing destinations for investor capital, with the example of a portfolio manager choosing SanDisk over Abivax. The transcript does not provide a definite sector forecast.

Takeaways

• The discussion leaves the effect of AI developments on semiconductor demand unresolved. Assess whether a company is likely to benefit from increased AI infrastructure spending or face pressure on its own revenue and investment plans.